Article info
PDFResearch
Trabectedin plus PLD versus PLD monotherapy in patients with platinum-sensitive relapsed ovarian cancer: a cost-effectiveness analysis in Spain
- Correspondence to Itziar Oyagüez Pharmacoeconomics & Outcomes Research Iberia, C/de la Golondrina 40A, Madrid 28023, Spain; ioyaguez{at}porib.com
Citation
Trabectedin plus PLD versus PLD monotherapy in patients with platinum-sensitive relapsed ovarian cancer: a cost-effectiveness analysis in Spain
Publication history
- Received April 18, 2012
- Accepted May 22, 2012
- First published June 20, 2012.
Online issue publication
May 13, 2016
Article Versions
- Previous version (13 May 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions